Tue, 28th Jul 2020 07:16
July 28 (Reuters) - AstraZeneca Plc said on Tuesday
its diabetes drug Farxiga met the main goal in a late-stage
trial testing the drug's effectiveness in treating patients with
chronic kidney disease.
The trial also met all of its secondary goals in chronic
kidney disease patients with and without type-2 diabetes".
(Reporting by Aakash Jagadeesh Babu in Bengaluru: Editing by
Bernard Orr)
April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negoti...
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:
(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while a...
(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe a...
(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', ...
Astrazeneca (AZN)